Liquids

Recipharm offer analytical support for drug discovery, pharmaceutical development and manufacturing through our global development facilities.

Recipharm offer a range of synthetic chemistry services through our global development facilities including advanced lead optimisation medicinal chemistry, process development and tech transfer to large scale GMP-manufacturing and other specialties.

Recipharm Inhalation Solutions™ offers an end-to-end service for inhalation drug products and devices spanning early stage development to commercial manufacture.Our dedicated team offers pharmaceutical companies a seamless outsourcing service from early stage development through to commercial manufacturing...

Through Recipharm Analytical Solutions™, we support customers with stand-alone analytical requirements. Our analytical development team has experience from developing hundreds of analytical methods every year, supporting development of formulations ranging from powder in capsules and IV solutions to ER tab...

Recipharm has extensive experience in the injectables area and supplies small volume parenterals in ampoules and vials, as well as in cartridges. State of the art leak detection and automatic inspection equipment is used and Recipharm’s full service offering is complete with secondary packaging and tempera...

Recipharm offers pharmaceutical contract development and manufacturing in ophthalmics including, sterile manufacturing of eye and ear drops in plastic multi-dose containers and  blow-fill-seal technology for single and as multi-dose use.

Recipharm offers pharmaceutical contract development and manufacturing of semi-solids including, APIs, creams, emulsions, gels, ointments, aerosols and suppositories. We have the capability to fill products in aluminum tubes, plastic tubes, syringes, aluminum cans, PVC or aluminum blist...

Recipharm offers pharmaceutical contract development and manufacturing of large commercial batch sizes of tablets, capsules or powders. 

Recipharm work with: • General APIs as well as some special substances • Conventional technologies, including fluid...

We keep both the end-user and our pharmaceutical partners at the forefront of our product design, producing injection devices created to facilitate patient-friendly administration and overcome formulation challenges, particularly for high viscosity formulations.

At Recipharm we deliver market-leading design, development, and manufacturing services for nasal spray devices to the global pharmaceutical market.

Deliver precise and effective treatments to your patients by partnering with Recipharm for your pMDI products. Backed by over 60 years of experience, we have overcome many pMDI product development challenges to provide you with high quality products.

In this written panel discussion experts in manufacturing in the pharmaceutical supply chain comment on the manufacturing landscape, how sustainable practices are being incorporated more readily, the challenges associated with this and the overall advantages. 

Your innovative drug. Our world-class production facilities. Discover the genius of working together.

Recipharm receives regulatory approval for the manufacture of a microbiome-based product for the prevention of Clostridioides difficile recurrent infection, under GenIbet Biopharmaceuticals and Seres Therapeutics. 

We are approaching the end of a year which saw global vaccine rollout for COVID-19, 44 novel drug approvals (to date) and the return of the CPHI Worldwide in-person event.

Lyophilisation or freeze drying is an important means to improve thermal stability of a drug product, according to Thomas Becker, Quality Director and Qualified Person, Recipharm. This is particularly true for those that are thermolabile, such as mRNA vaccine candidates.

A summary exploring Recipharm’s key considerations when it comes to developing effective analytical methods for drug projects.

With so many outsourcing options available, selecting the CDMO that is the right fit for any particular sponsor company can be a challenging task.

In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.

Sponsors within the biopharmaceutical industry are increasingly turning to outsourcing for several reasons; remaining competitive and flexible within a quickly evolving sector, gaining access to manufacturing capacity and state-of-the-art equipment and scaling up to the commercial level are just three examples.

In January 2020 the European Commission published some proposed significant revisions to Annex 1, the EU’s good manufacturing practice (GMP) guide for the manufacture of sterile products. In the following three-month consultation period, affected organisations and stakeholders from over 70 different countries submitted more than 2,000 comments to the proposed update.